Amarin Corporation plc (NASDAQ:AMRN) is one of the best performing pharma stocks in 2025. Amarin Corporation plc (NASDAQ:AMRN) announced select unaudited 2025 financial highlights on January 8, releasing a summary of key 2025 operational accomplishments and outlining the 2026 priorities. The company reported that it attained positive cash flow in fiscal Q4 2025 earlier than previously forecasted, driven by a meaningful reduction in its operating expenses and its long-term and exclusive partnership with Recordati S.p.A. to commercialize VAZKEPA® across 59 countries, with a focus on Europe.
Amarin Corporation plc (NASDAQ:AMRN) believes it is on track for sustainable positive annual cash flow in 2026, supported by a full year of cost savings from its restructuring plan, the majority of expenses related to the plan already incurred in 2025, and continued efficient revenue generation across all markets.
It reported a year-end 2025 cash balance of $303 million, reflecting a growth of $16 million compared to $287 million in Q3 2025. The company did not report any debt, and expects its fiscal Q4 2025 net revenue to be in the range of $48 to $53 million. Fiscal year 2025 net revenue is expected to be in the $212 to $217 million range.
Amarin Corporation plc (NASDAQ:AMRN) is a pharmaceutical company involved in the development and commercialization of therapeutics targeting cardiovascular health. The company’s focus is on developing and commercializing Vascepa capsules.
While we acknowledge the potential of AMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
